Varenhorst, C., James, S., Erlinge, D., Brandt, J. T., Braun, O. Ö., Man, M., . . . Close, S. L. (2009). Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Oxford University Press.
Chicago Style CitationVarenhorst, Christoph, et al. Genetic Variation of CYP2C19 Affects Both Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel but Not Prasugrel in Aspirin-treated Patients With Coronary Artery Disease. Oxford University Press, 2009.
Cita MLAVarenhorst, Christoph, et al. Genetic Variation of CYP2C19 Affects Both Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel but Not Prasugrel in Aspirin-treated Patients With Coronary Artery Disease. Oxford University Press, 2009.